Aim of the study
proteinuria, glomerulonephritis, diabetic kidney diseases
GLOMERULONEPHRITIS
To examine the effect of the sodium–glucose transporter 2 inhibitor (empagliflozin) on proteinuria and kidney function progression, in patients with glomerulonephritis not due to diabetic kidney diseases.